[go: up one dir, main page]

GT201800020A - Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) - Google Patents

Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Info

Publication number
GT201800020A
GT201800020A GT201800020A GT201800020A GT201800020A GT 201800020 A GT201800020 A GT 201800020A GT 201800020 A GT201800020 A GT 201800020A GT 201800020 A GT201800020 A GT 201800020A GT 201800020 A GT201800020 A GT 201800020A
Authority
GT
Guatemala
Prior art keywords
csf
inhibitors
factor receptor
stimulating factor
colony stimulating
Prior art date
Application number
GT201800020A
Other languages
English (en)
Inventor
John L Kane Jr
Markus Metz
Vinod Patel
Andrew Scholte
Patrick Shum
Limli Wei
Claude Barberis
Mark Czekaj
Paul Erdman
Barret Giese
Michael Kothe
Tieu-Binh Le
Jinyu Liu
Liang Ma
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of GT201800020A publication Critical patent/GT201800020A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)

Abstract

COMPUESTOS DE FÓRMULAS QUE SON ÚTILES COMO INHIBIDORES DEL RECEPTOR DEL FACTOR ESTIMULADOR DE COLONIAS 1 (CSF-1R) ("INHIBIDORES DE CSF 1R").
GT201800020A 2015-07-20 2018-01-15 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) GT201800020A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194619P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
GT201800020A true GT201800020A (es) 2019-10-21

Family

ID=56551024

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201800020A GT201800020A (es) 2015-07-20 2018-01-15 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Country Status (27)

Country Link
US (3) US11274108B2 (es)
EP (1) EP3325471A1 (es)
JP (4) JP6898914B2 (es)
KR (1) KR102665765B1 (es)
CN (1) CN107922396B (es)
AR (1) AR105392A1 (es)
AU (3) AU2016297558B2 (es)
BR (1) BR112018001017B1 (es)
CA (2) CA2993018A1 (es)
CL (1) CL2018000140A1 (es)
CO (1) CO2018001621A2 (es)
CR (1) CR20180109A (es)
DO (1) DOP2018000008A (es)
EC (1) ECSP18012103A (es)
GT (1) GT201800020A (es)
IL (3) IL305843B2 (es)
MA (1) MA42023B2 (es)
MX (2) MX388540B (es)
MY (1) MY186368A (es)
PE (1) PE20180573A1 (es)
PH (1) PH12018500140A1 (es)
RU (1) RU2748884C2 (es)
SG (1) SG10201912699RA (es)
TN (1) TN2018000020A1 (es)
TW (1) TWI734693B (es)
WO (1) WO2017015267A1 (es)
ZA (1) ZA201800082B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG193982A1 (en) 2011-03-28 2013-11-29 Mei Pharma Inc (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
EP3630118A4 (en) 2017-05-23 2021-03-31 MEI Pharma, Inc. COMBINATION THERAPY
KR102636383B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN111212643A (zh) 2017-08-14 2020-05-29 梅制药公司 联合疗法
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
EP3920928A4 (en) 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3950063A4 (en) * 2019-03-29 2022-11-30 Kowa Company, Ltd. NOVEL AZAINDO DERIVATIVE
CA3185649A1 (en) 2020-07-20 2022-01-27 Bakary-Barry Toure Indole compounds as androgen receptor modulators
JP2023542041A (ja) * 2020-09-21 2023-10-04 ハチソン メディファルマ リミテッド ヘテロ芳香族化合物及びその使用
CN118271317A (zh) * 2020-09-25 2024-07-02 成都嘉葆药银医药科技有限公司 1H-吡咯并[2,3-c]吡啶类化合物及其应用
EP4267573A1 (en) * 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2022140528A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN116848110A (zh) * 2020-12-23 2023-10-03 建新公司 氘代集落刺激因子-1受体（csf-1r）抑制剂
US20250188077A1 (en) * 2022-03-25 2025-06-12 Jumbo Drug Bank Co., Ltd. Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor
WO2023249989A1 (en) 2022-06-22 2023-12-28 Genzyme Corporation Solid forms of deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN118206507A (zh) * 2023-03-22 2024-06-18 中国医学科学院医药生物技术研究所 一种含硒化合物及其制备方法与用途
TW202535870A (zh) * 2023-10-26 2025-09-16 日商大塚製藥股份有限公司 作為csf1r抑制劑之化合物

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612323A (en) 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS61118380A (ja) * 1984-11-14 1986-06-05 Shionogi & Co Ltd 新規な１，４−ベンゾジオキサンおよび１，４−ベンゾジオキシン誘導体ならびにその製造法
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
JPH07116183B2 (ja) * 1987-03-31 1995-12-13 三菱化学株式会社 チアジアゾ−ル誘導体及びこれを有効成分とする殺虫殺ダニ剤
DE58907554D1 (de) 1988-08-05 1994-06-01 Basf Ag Phenoxyalkylsubstituierte Heteroaromaten, Verfahren zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schädlingen.
ZA913760B (en) * 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
DE4227791A1 (de) 1991-08-24 1993-02-25 Schering Ag Pyrrolo (2,3c)-pyridinderivate, deren herstellung und verwendung in arzneimitteln
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
AU4348593A (en) * 1992-06-25 1994-01-24 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
FR2693197B1 (fr) * 1992-07-03 1994-09-23 Synthelabo Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique.
PL176526B1 (pl) 1992-12-17 1999-06-30 Pfizer Pirolopirymidyny jako związki o działaniu antagonistów czynnika uwalniającego kortykotropinę
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JPH07138259A (ja) 1993-06-30 1995-05-30 Asahi Glass Co Ltd イミダゾール誘導体の製造法
JPH09202774A (ja) 1996-01-25 1997-08-05 Green Cross Corp:The ２−アリールキノリン類およびその製造方法
JPH101471A (ja) * 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
US6060480A (en) 1996-08-30 2000-05-09 Yoshitomi Pharmaceutical Industries, Ltd. Preventives/remedies for muscle tissue degenerations
US6172084B1 (en) 1997-06-19 2001-01-09 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
CN1268942A (zh) * 1997-06-27 2000-10-04 藤泽药品工业株式会社 磺酰胺化合物及其药物用途
IL133800A0 (en) * 1997-07-03 2001-04-30 Du Pont Pharm Co Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
US6130333A (en) * 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
JP2001039874A (ja) 1999-07-28 2001-02-13 Welfide Corp 肺高血圧症予防治療剤
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
JP4292742B2 (ja) * 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
DE60318198T2 (de) 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
JP2007500253A (ja) 2003-01-22 2007-01-11 イーライ リリー アンド カンパニー ステロイドホルモン核内受容体のインドール誘導体モジュレーター
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1613311A4 (en) 2003-03-27 2010-04-14 Univ Emory HIF-1 INHIBITORS
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
CA2553724A1 (en) * 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
EP1805177B9 (en) 2004-09-03 2010-09-15 Yuhan Corporation Pyrrolo[3,2-c]pyridine derivatives and process for the preparation thereof
TWI278682B (en) 2004-11-23 2007-04-11 Ind Tech Res Inst Fiber optic interferometric position sensor and measuring method thereof
AR052419A1 (es) 2004-12-01 2007-03-21 Osi Pharm Inc Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
FR2883286B1 (fr) * 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
US7846941B2 (en) * 2005-05-17 2010-12-07 Plexxikon, Inc. Compounds modulating c-kit and c-fms activity and uses therefor
MX2007016463A (es) 2005-06-22 2008-03-04 Plexxikon Inc Derivados de pirrolo [2,3-b] piridina como inhibidores de proteina cinasa.
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
AU2006297798B2 (en) 2005-09-21 2013-01-31 Decode Genetics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0717317A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Modularoes da proteína cinase triazalopiridazina
SI2081937T1 (sl) 2006-10-23 2012-11-30 Sgx Pharmaceuticals Inc Triazolopiridazinski modulatorji proteinskih kinaz
WO2008064219A1 (en) * 2006-11-22 2008-05-29 Johnson Controls Technology Company Multichannel evaporator with flow mixing manifold
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US8546394B2 (en) * 2007-04-17 2013-10-01 Bristol-Myers Squibb Company Substituted [1,2,4]triazolo[4,3-A]pyrazine 11-beta-hydroxysteroid dehydrogenase inhibitors
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
EA201070572A1 (ru) 2007-11-07 2010-12-30 Фолдркс Фармасьютикалз, Инк. Модуляция транспорта белков
EP2273882A4 (en) 2008-05-13 2011-07-13 Poniard Pharmaceuticals Inc BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CA2733554A1 (en) 2008-08-18 2010-02-25 Yale University Mif modulators
US20110269788A1 (en) 2008-12-29 2011-11-03 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
JP5649644B2 (ja) 2009-04-22 2015-01-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
KR101871436B1 (ko) 2010-05-17 2018-06-27 인코젠 쎄라퓨틱스 프라이빗 리미티드 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3ｈ-이미다조[4,5-ｂ]피리딘 및 3,5- 디치환 -3ｈ-[1,2,3]트리아졸로[4,5-ｂ] 피리딘 화합물
WO2011156632A2 (en) * 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
EP2643297A1 (en) 2010-11-24 2013-10-02 Allergan, Inc. Indole derivatives as modulators of s1p receptors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
US8748435B2 (en) * 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
EP2714688B1 (en) 2011-05-26 2016-02-24 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
JP6055468B2 (ja) 2011-07-15 2016-12-27 ヴィーブ ヘルスケア ユーケー リミテッド アザインドール化合物及びｈｉｖを治療するための方法
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
SI2766359T1 (sl) 2011-10-14 2016-09-30 Ambit Biosciences Corporation Heterociklične spojine in njihova uporaba kot modulatorjev receptorja tirozin kinaze tipa III
CN104010504B (zh) * 2011-11-03 2016-04-06 默沙东公司 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途
US9174980B2 (en) * 2012-01-31 2015-11-03 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
JP6200903B2 (ja) * 2012-02-17 2017-09-20 キネタ フォー エルエルシー アレナウイルス感染症の治療のための抗ウイルス薬
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
CN104470916A (zh) 2012-06-15 2015-03-25 爱尔兰詹森研发公司 新颖的作为呼吸道合胞病毒抗病毒剂的被苯并咪唑取代的1,3-二氢-2h-苯并咪唑-2-酮衍生物
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
AU2013348018A1 (en) * 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
CN104109166B (zh) 2013-04-17 2017-06-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
BR112016015236B1 (pt) * 2013-12-30 2023-11-14 Array Biopharma Inc. Composto, composições farmacêuticas, usos de um composto e método in vitro de inibição da atividade da proteína quinase erk
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
KR102139847B1 (ko) * 2014-05-01 2020-07-31 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
SG11201704872RA (en) 2014-12-18 2017-07-28 Genzyme Corp Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors
WO2016123392A2 (en) * 2015-01-29 2016-08-04 Sanford-Burnham Medical Research Institute Pyrazolopyrimidines as inhibitors of glucocorticoid receptor translocation
CN107922396B (zh) 2015-07-20 2022-08-05 建新公司 集落刺激因子-1受体(csf-1r)抑制剂
CN110526916B (zh) 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Also Published As

Publication number Publication date
JP2024028845A (ja) 2024-03-05
JP2021107414A (ja) 2021-07-29
SG10201912699RA (en) 2020-02-27
AU2016297558B2 (en) 2021-03-25
IL256964A (en) 2018-03-29
JP7401482B2 (ja) 2023-12-19
TWI734693B (zh) 2021-08-01
AU2021204116B2 (en) 2022-12-01
RU2018106060A3 (es) 2019-12-13
IL305843A (en) 2023-11-01
KR20180030199A (ko) 2018-03-21
PE20180573A1 (es) 2018-04-04
TN2018000020A1 (en) 2019-07-08
US12503477B2 (en) 2025-12-23
WO2017015267A1 (en) 2017-01-26
CN107922396B (zh) 2022-08-05
IL305843B2 (en) 2025-01-01
JP6898914B2 (ja) 2021-07-07
IL276292B2 (en) 2024-02-01
MX2021015102A (es) 2022-02-21
AU2016297558A1 (en) 2018-03-08
MX2018000880A (es) 2018-08-24
CN107922396A (zh) 2018-04-17
IL305843B1 (en) 2024-09-01
US11274108B2 (en) 2022-03-15
NZ739951A (en) 2024-02-23
US20190016707A1 (en) 2019-01-17
US20240217991A1 (en) 2024-07-04
BR112018001017A2 (pt) 2018-09-18
BR112018001017B1 (pt) 2024-02-15
CA2993018A1 (en) 2017-01-26
RU2018106060A (ru) 2019-08-20
AR105392A1 (es) 2017-09-27
CR20180109A (es) 2018-05-03
MA42023B2 (fr) 2022-01-31
KR102665765B1 (ko) 2024-05-10
ZA201800082B (en) 2018-12-19
IL276292A (en) 2020-09-30
EP3325471A1 (en) 2018-05-30
MY186368A (en) 2021-07-16
JP2025094019A (ja) 2025-06-24
ECSP18012103A (es) 2018-04-30
IL256964B (en) 2021-10-31
TW201716393A (zh) 2017-05-16
DOP2018000008A (es) 2018-05-15
US20220396588A1 (en) 2022-12-15
JP2018524381A (ja) 2018-08-30
RU2748884C2 (ru) 2021-06-01
AU2023201013A1 (en) 2023-03-23
AU2023201013B2 (en) 2025-02-06
MX388540B (es) 2025-03-20
CA3217238A1 (en) 2017-01-26
IL276292B1 (en) 2023-10-01
JP7652867B2 (ja) 2025-03-27
AU2021204116A1 (en) 2021-07-15
CL2018000140A1 (es) 2018-08-17
PH12018500140A1 (en) 2018-07-23
CO2018001621A2 (es) 2018-02-28

Similar Documents

Publication Publication Date Title
GT201800020A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
EA202092609A1 (ru) Антитела к cd38 для лечения острого миелолейкоза
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2016002157A1 (es) Anticuerpos anti-cd38 para el tratamiento de leucemia linfoide aguda
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
UY36311A (es) Indazoles sustituidos con bencilo
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA201890052A1 (ru) Регуляторы nrf2
CO2018007221A2 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
MX2017008442A (es) Uso de picolinamidas como fungicidas.
EA201890185A1 (ru) Способы лечения опосредованных гепсидином нарушений
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
ECSP16074207A (es) Pirazinas moduladoras de gpr6
MX381643B (es) Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr.